ARTICLE 1

Anticoagulants/Antithrombotics

 Frumkin K. Rapid reversal of warfarin-associated hemorrhage in the emergency department by prothrombin complex concentrates. *Ann Emerg Med.* 2013;62(6):616-26.

Introduction

2016 LLSA Review

Articles 1, 9, 11, 12

Brian Felice, MD Beaumont Health System – Royal Oak November 13, 2017

- 7-10x increased risk of intracranial hemorrhage (ICH) if anticoagulated with warfarin
- 60% mortality with intracranial hemorrhage
- Rapid reversal \rightarrow slow hematoma expansion
- Warfarin inhibits synthesis of Vitamin K dependent coagulation factors
 - Factors II, VII, IX, X

Options for Reversal

- Vitamin K
- Fresh Frozen Plasma (FFP)
- Recombinant Factor VIIa (rFVIIa)
- Prothrombin Complex Concentrate (PCC)

Vitamin K

- Required for any sustained reversal of warfarin related hemorrhage
- Up to 4 hours for desired effects
- Cheap \rightarrow \$15-20 for 10 mg
- IM/SC \rightarrow No
- ORAL \rightarrow effective
- IV → faster
 - 5-10 mg if life threatening hemorrhage
 - Administer slowly

Fresh Frozen Plasma (FFP)

- Requires ABO compatibility testing and 30-60 min to thaw
- Poor evidence of effectiveness in ICH
- Slow \rightarrow 13 48 hours for desired effect
- Price → approx. \$60
- Minimum dose \rightarrow 4 Units (15 cc/kg) for 70 kg person

Recombinant Factor VIIa

- Off label use for non-hemophiliac hemorrhage
- Fast \rightarrow < 1 hour for INR reversal
- Risk of thrombosis \rightarrow 10 20% (high)
- Dose \rightarrow 90 ug/kg for ICH (maybe less)
- INR not accurate to follow after rFVIIa
- Remain consideration for those pts with religious restrictions
- Approximately \$1700 for 1 mg of NovoSeven

Prothrombin Complex Concentrate (PCC)

- Derived from pooled human plasma
- 3 Factor-PCC → contains Factor II, IX, X, Protein C and S , + heparin
- 4 Factor-PCC (Kcentra) → contains Factor II, VII, IX, X, Protein C and S, + heparin
- Approved for use in US \rightarrow 2013

Prothrombin Complex Concentrate (PCC)

- Rapid reversal of INR
 - Within 10 30 minutes
 - Can last up to 6 hours
- Risk of thrombotic adverse events \rightarrow 1.5% (0.9 3.8%)
- Potential for transmission of infectious disease
- Contraindications \rightarrow DIC, decompensated liver disease, ongoing warfarin tx, HIT
- Expensive → \$2000-2500 for 2000 units

Prothrombin Complex Concentrate (PCC)

- Dosing \rightarrow 25-50 IU/kg
- Small volume (usually less than 100 mL)
- No need for ABO-compatibility testing
- Repeat INR 15 minutes post-administration of PCC to guide further therapy
- PCC better than FFP and rFVIIa for warfarin reversal for brain hemorrhage
 - Improved neurologic outcomes
 - Reduced hematoma growth

ial hemorrhuge

- and availability): usur INR >1.5 ima (15 mL/kg) himed with firsh fi

- ninistration der a second 25 IU/kg do

KEY POINTS

- · For reversal of life-threatening bleeding related to warfarin to all patients Vitamin K should be administered early via IV route
- · FFP should be given when other agents are unavailable
- PCC (preferably 4-factor) is a great option for warfarin reversal, especially in brain hemorrhage Low Volume
 - Faster INR reversal
 - · Increasing evidence of superiority to other modalities
- When using 3-factor PCC, consider adding FFP or rFVIIa (lack of factor VII) If used alone, check the INR 15 minutes aft

ARTICLE 9

Liver

• Bernal W, Wendon J. <u>Acute liver failure</u>. N Engl J Med. 2013;369(26):2525-34.

Objective

• Review article

- Define Acute Liver Failure
- Review Evidence, Guidelines, and Specific Recommendations
- Conflicts → lead author on board (2) and speaker (2) different medical/pharmaceutical companies

General Information

- Rare
- 1 in 100,000 (developed world)
- Most common in previously healthy adults in their 30s
- Multiorgan failure and death occurring in up to 50% of cases
- Very limited evidenced-based data to guide management due to rarity
- · Survival improved with aggressive critical care and transplant

Definitions

- Fulminant Hepatic Failure → severe liver injury (potentially reversible) with onset of hepatic encephalopathy within 8 weeks of first symptoms, in absence of pre-existing liver disease.
- Hyperacute Liver Failure → usually one week or less; usually caused by acetaminophen toxicity or viral infection.
- Subacute Liver Failure → usually weeks to months; often resulting from idiosyncratic drug reactions or idiopathic causes
 - Consistently worse outcomes, despite coagulopathy/encephalopathy
 May be confused with chronic liver disease

Causes of Acute Liver Failure

• Viral Infections – Hepatitis A, B, E

- Predominant cause in developing countries
- 50% mortality
- Drug-Induced accounts for 50% of cases in the USA
- Acetaminophen-Induced → most common, dose dependent (predictable)
 Idiosyncratic → can be independent of dose (unpredictable)
- Age, Coagulopathy, Elevated LFTs are risk factors for increased mortality
- Other Causes
 - Acute ischemic hepatocellular injury, hypoxic hepatitis, neoplastic infiltration, acute Budd-Chiari syndrome, heat stroke, mushroom ingestion, Wilson's Disease

Initial Treatment of Acute Liver Failure

- Aggressive supportive/critical care
 - Improve systemic perfusion
 - Fluids, pressor support
 Airway protection
 - Consider intubation for airway protection in severe encephalopathy
 - Infection control
 - Functionally immunosuppressedInfection will exacerbate encephalopathy
- Overt bleeding uncommon despite coagulopathy
- Early consideration to transplant/liver center

Acetylcysteine

- · Early treatment improves outcomes in acetaminophen-induced toxicity
- Beneficial to patients with other causes of Acute Liver Failure
 - Complex antioxidant and immunologic effects Improved survival rates among patients with low-grade encephalopathy in randomized controlled trials

Cardio-respiratory Dysfunction

- · Low circulatory volumes IVF, pressor support as needed (norepinephrine)
- Echo
- Adrenal insuffiency (possible) Stress dose steroids
- Respiratory Support Early intubation

Neurologic Complications/Encephalopathy

- Acute Liver Failure with high grade encephalopathy Poor Prognosis
- Subacute Liver failure even low grade encephalopathy · Poor Prognosis
- Intracranial HTN from Cerebral Edema \rightarrow Leading Cause of Death
 - · Poorly understood; systemic/local toxins, including ammonia
 - May be precipitated or worsened by infection/hypotension
 - Treatment with antibiotics or lactulose may be harmful in ALF (not chronic)
 - Prevent IC-HTN with sedation, 3% NaCl, consider hypothermia

Renal Dysfunction

- May occur in >50% of patients with Acute Liver Failure
- · More common in elderly and those with acetaminophen-induced ALF
- · Renal dysfunction often resolves with resolution of liver failure
- If renal replacement therapy required: CRRT (continuous) > intermittent

Treatment

- Aggressive Supportive Care
 - Large volume infusion should be avoided

 - Canje volume influsion situati e voluceu
 Can lead to hyponatremia and cerebral edema
 Increased risk of hypoglycemia due to poor glycogen stores
 May require glucose influsion
 Balance protein supplementation, while monitoring ammonia levels
- Identify Transplant Candidates before Multiorgan Failure
 - Multiple criteria (King's College, Clichy, Japanese Criteria)
 Indicators → Encephalopathy, Age, and Severity (coagulopathy/jaundice)

Liver Transplantation

Less than 10% for patients with Acute Liver Failure
 Survival rates lower than elective liver transplantation

ARTICLE 11

Small Bowel Obstruction

• Taylor MR, Lalani N. Adult small bowel obstruction. Acad Emerg Med. 2013;20(6):528-44.

General Information/Objectives

- Systematic review and meta-analysis
- Identify evidence based aspects of History, Physical Exam, imaging in diagnosis of SBO
- Determine prevalence of SBO in prospective based ED studies
- Test-treatment threshold to determine when to begin treatment vs further diagnostics to confirm SBO

General Information

- 300,000 admissions in US annually
- 70% admitted through the ED (>200,000/year)
- 2% of all abdominal pain complaints
- 15% of patients admitted to surgical unit from ED have SBO
- Causes of SBO
- Adhesions from previous surgery (75% of all cases)
 Neoplasms, hernias, crohn's disease
- Interplasms, nernias, crohn's disease
 High complication rate
 - Strangulation \rightarrow 30%; Bowel Necrosis \rightarrow 15%

Methods

- Searched articles from 1946-2011 (MEDLINE and EMBASE)
- > 7700 articles → Applied exclusion criteria to screen articles
 Exclusion Criteria: case studies with insuff. data to develop 2 x 2 table, pediatric population studies, tests not readily available to EP, those focused on single radiographic sign, those focused on treatment, and studies that were not primary research
- 22 FINAL articles (12 prospective, 10 retrospective)
 - QUADAS-2 (quality assessment)
 - Data analyzed/pooled to calculate sensitivity/specificity/likelihood ratios
 Separate info gathered on prevalence and management of SBOs
 - Test/treatment thresholds

↓ ↓ Prime internation ↓ Prima internation

Results – History

- No components of history that could reliable/accurately predict SBO
- History of previous abdominal surgery had best combination + LR = 3.86 and – LR = 0.19
- History of constipation
- + LR = 8.8 and LR = 0.59
- Very few components of physical exam could be reliably used for diagnosis of SBO
- Abdominal Distention on physical exam was best sign
 + LR = 16.8 and LR = 0.34

Results – Physical

- Very few components of physical exam could be reliably used for diagnosis of SBO
 - Abnormal Bowel Sounds
 + 6.33 and LR = 0.27
 - Abdominal Distention on physical exam was best sign
 + LR = 16.8 and LR = 0.34


Results - Imaging

Imaging Study	+ Likelihood Ratio	- Likelihood Ratio
X-Ray	1.55	0.43
CT Scan	3.62	0.18
MRI	6.77	0.12
Bedside Ultrasound	9.55	0.13
Formal Ultrasound	14.1	0.04

• CT is most sensitive and specific for SBO:

 Continuous loops of bowel ≥ 2.5 cm present proximal to collapsed loops of bowel (transition point)

Test-Treat Threshold



Pretest probability for further testing: > 1.5%
Probability for initiating treatment: > 20.7%

Conclusions

- Causes of SBO: adhesions (most common), neoplasm, hernia, crohn's
- Abdominal pain + constipation, or Abdominal pain + prior hx of SBO increases chance of SBO
- Physical exam findings of abdominal distention and abnormal bowel sounds increases chance of SBO
- CT is most sensitive and specific for making the diagnosis with finding of transition point.
- US can show SBO with highest likelihood ratio, but will not show transition point

ARTICLE 12

Pericarditis

 Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. <u>A randomized</u> trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8.

General Information

- Colchicine historically has been used for treatment of chronic pericarditis
- Prospective trial to look at use of colchicine for acute pericarditis
 Multi-center, Double blinded, Randomized Control Trial

Methods

- 240 Patients \rightarrow 120 received colchicine 0.5 mg bid (> 70 kg) (**No loading dose**) vs. placebo + usual therapy (NSAIDS, aspirin, steroids) • Follow up a1 week, 13, 6, 12 months, and then every 6 months
- Primary Outcome → Incessant (persistent) or Recurrent Pericarditis
- Secondary outcomes \rightarrow symptoms at 72 h, remission within 1 week, # of recurrences, tamponade, etc
- Inclusion: ≥18 yo + acute first episode
 First Episode → 2 of the following: typical CP, friction rub, EKG findings, new pericardial effusion
- Exclusion: cancer, severe liver disease, elevated Cr, pregnant, TB, blood dyscrasia, IBD

Definitions

Recurrent Pericarditis

- Documented first attack of acute pericarditis
- · Symptom free interval of 6 weeks or longer
- Evidence of recurrent pericarditis Recurrent Pain + 1 or more of the following:
 - Pericardial Friction Rub, ECG changes, Echo findings of effusion, Elevation in WBC, ESR, or CRP

- Incessant (persistent) Pericarditis
 - Symptom free interval of less than 6 weeks
 - · Evidence of recurrent pericarditis (as above)

Results – Trial Outcomes

- Primary Outcome → Recurrent Pericarditis
 - + Less frequent in colchicine group (16.7% v 37.5%, p < .001)
 - Relative Risk Reduction in colchicine subset of 0.56 (95% CI)
- Secondary Outcomes
 - Statistically significant decrease in symptoms at 72 hours with colchicine
 - Decreased number of recurrences per patient with colchicine
 - Decreased hospitalization with colchicine
 - Colchicine improved rate of remission within in 1 week of treatment

Results – Trial Outcomes

Table 2. Trial Outcomes.*				
Outcome	Placebo (N-120)	Colchicine (N = 120)	P Value	
Incessant or recurrent pericarditis: primary end point - no. (%)	45 (37.5)	20 (16.7)	<0.001	
Symptom persistence at 72 hr no. (%)	48 (40.0)	23 (19.2)	0.001	
Remission at 1 wk - no. (%)	70 (58.3)	102 (85.0)	<0.001	
Incessant course — no. (%)	20 (16.7)	9 (7.5)	0.046	
Recurrent course no. (%)	25 (20.8)	11 (9.2)	0.02	
No. of recurrences per patient	0.52±0.81	0.21±0.52	0.001	
Time to first recurrence - wk	17.7±9.0	24.7±11.0	<0.001	
Cardiac tamponade — no. (%)	3 (2.5)	0	0.25	
Constrictive pericarditis no. (%)	1 (0.8)	0	1.00	
Pericarditis-related hospitalization no. (%)	17 (14.2)	6 (5.0)	0.02	
Mean follow-up mo	22.3±8.7	22.9±8.7	0.61	

Results – Adverse Events

- Adverse Events were similar in the two study groups
- Diarrhea was the most common side effect • Occurred in less than 10% of the patients.

Results – Adverse Events

Adverse Event	Placebo (N=120)	Colchicine (N=120)	P Value
		10. (%)	
Overall	12 (10.0)	14 (11.7)	0.84
Gastrointestinal disorder#	10 (8.3)	11 (9.2)	0.67
Hepatotoxicity	1 (0.8)	2 (1.7)	
Myotoxicity	0	0	
Alopecia	1 (0.8)	1 (0.8)	
Other	0	0	
Serious adverse event\$	0	0	
Drug discontinuation	10 (8.3)	14 (11.7)	0.52
Physician decision	9 (7.5)	12 (10.0)	
Patient decision	1 (0.8)	2 (1.7)	

Conclusions

- · Colchicine was shown to reduce the rates of both recurrent and incessant (persistent) pericarditis compared to placebo.
- Colchicine also was shown to reduce length of symptoms, number of recurrences, and hospitalizations.
- Results seen without loading dose (0.5 mg BID), reducing adverse side effects.

11/6/2017

Conclusions (cont.)

- Relative Risk Reduction (RRR) Colchicine Group: 0.56
- Number Needed to Treat (NNT) 4
- Colchicine (0.5 mg BID x 3 months) + usual treatment for acute pericarditis, significantly reduced rate of persistent and recurrent symptoms